Status:
NOT_YET_RECRUITING
Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure
Lead Sponsor:
Nebraska Methodist Health System
Conditions:
Severe Preeclampsia
Eclampsia Preeclampsia
Eligibility:
FEMALE
19+ years
Phase:
PHASE3
Brief Summary
The goal of this study is to compare levetiracetam to magnesium sulfate for the prevention of eclamptic seizures in pregnant persons with severe preeclampsia that are 32 or more weeks pregnant. This i...
Detailed Description
Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure: A Randomized Controlled Trial Study Protocol 1. Study Title: Levetiracetam Compared to Magnesium Sulfate for Preventio...
Eligibility Criteria
Inclusion
- Pregnant or postpartum women aged 19 years or older
- Diagnosed with preeclampsia with severe features, superimposed preeclampsia or HELLP syndrome
- At risk for eclampsia and eligible for seizure prophylaxis
- Less than 2 hours exposure to magnesium sulfate or greater than 48 hours since last dose.
- Admitted or plan to proceed with delivery
Exclusion
- \<32 weeks estimated gestational age
- History of epilepsy or seizure disorders unrelated to pregnancy
- Allergy or contraindication to Levetiracetam or Magnesium Sulfate
- Severe renal impairment (Oliguria \<120ml in 4 hours)
- Plan for neonatal comfort care
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2034
Estimated Enrollment :
1240 Patients enrolled
Trial Details
Trial ID
NCT07220902
Start Date
January 1 2026
End Date
July 1 2034
Last Update
October 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Women's Hospital
Omaha, Nebraska, United States, 68022